Strategies for maximizing and extending response to biologic therapy

Gastroenterology and Hepatology

Volumn 5, Issue 4, 2009, Pages 6-8

  Rubin, David T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL FACTOR; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; MONOCLONAL ANTIBODY; NATALIZUMAB; PEGYLATED ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

BIOLOGICAL THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISABILITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; LONG TERM CARE; OPEN STUDY; PATIENT IDENTIFICATION; REMISSION; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 66949135789     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Hanauer SB. Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005;2:493.
2. Hanauer SB. Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord. 2007;7 Suppl 2:S17-22.
3. Schreiber S, Reinisch W, Colombel J, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology. 2007; 132:A-147 Abstract 985.
4. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol For Crohn's disease. N Engl J Med. 2007;357:239-50.
5. Lionetti P Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease durarion in paediatric Crohn's disease. Aliment Pharmacol Ther. 2003;18: 425-31.
6. Matsumoto T, Iida M, Motoya S, et al. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey. Dis Colon Rectum. 2008;51:916-23.
7. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873; quiz 1165-6.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
9. Baert R Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
10. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-9.
11. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-53.
12. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007:146:829-38.
13. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-33; quiz 591.
14. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-85.
15. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
16. Sandborn WJ, Hanauer S, Loftus EV, Jr., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:1984-9.
17. Hinojosa J, Garcia S, Bastida G, et al. Efficacy and safety of 4 weeks of adalimumab treatment in subjects with active luminal Crohn's disease who lost response or showed intolerance to infliximab. Gastroenterology. 2006; 130A-656 Abstract Wl 197.